Other equities research analysts also recently issued research reports about the stock. Deutsche Bank AG restated a buy rating and issued a GBX 5,600 ($73.10) price target on shares of Shire PLC in a research report on Monday, June 13th. Royal Bank Of Canada restated an outperform rating on shares of Shire PLC in a research report on Friday, July 22nd. Jefferies Group upped their price target on shares of Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the company a buy rating in a research report on Wednesday, August 3rd. Citigroup Inc. restated a buy rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Finally, Credit Suisse Group AG upped their price target on shares of Shire PLC from GBX 5,000 ($65.27) to GBX 5,200 ($67.88) and gave the company an outperform rating in a research report on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of GBX 5,828 ($76.07).
Shire PLC (LON:SHP) opened at 5088.00 on Monday. The stock’s market capitalization is GBX 34.74 billion. The firm has a 50-day moving average of GBX 4,983.50 and a 200-day moving average of GBX 4,550.18. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00.
The firm also recently declared a dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 8th will be issued a dividend of GBX 3.51 ($0.05) per share. The ex-dividend date of this dividend is Thursday, September 8th. This represents a dividend yield of 0.07%.
In other Shire PLC news, insider Dominic Blakemore purchased 133 shares of the business’s stock in a transaction dated Friday, September 30th. The shares were acquired at an average price of GBX 5,010 ($65.40) per share, for a total transaction of £6,663.30 ($8,697.69).
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.